Zobrazeno 1 - 10
of 542
pro vyhledávání: '"Alan Menter"'
Autor:
Alan Menter
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 12, Pp 2929-2932 (2023)
Abstract This Summary of Research overviews the results of the VOLTAIRE-X study (NCT03210259), which looked at what happened when people with plaque psoriasis continually took the adalimumab reference product (adalimumab RP; known by the brand name H
Externí odkaz:
https://doaj.org/article/ca43bcbbc4ca44f082222b725e33a5fe
Publikováno v:
European Medical Journal Allergy & Immunology (2023)
Psoriasis is a chronic inflammatory skin condition with a significant global burden of disease and a wide array of potential treatment options, ranging from topical to systemic therapies. There are currently 11 biologic agents approved by the U.S. Fo
Externí odkaz:
https://doaj.org/article/0099ff5c1a8e4b638bb2b6373433b4fa
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 5, Pp 1111-1120 (2020)
Abstract Introduction Psoriasis is a chronic, inflammatory disease, which ranges in severity from mild to severe. Although topical therapies are frequently used to treat mild disease, they are not routinely used to treat patients with moderate-to-sev
Externí odkaz:
https://doaj.org/article/187c7829b8ea407aa50b6c6dab3b5130
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 5, Pp 1121-1135 (2020)
Abstract Introduction Psoriasis is a chronic immune-mediated inflammatory skin disease that occurs in 2.5–3.5% of the general population. Infliximab (INF), a TNF-α inhibitor biologic agent, is a long-standing efficacious treatment for psoriasis; h
Externí odkaz:
https://doaj.org/article/571d40f97d274892abf17391068e582d
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 4, Pp 615-621 (2020)
Abstract While biologic therapies for psoriasis are effective for many patients, some patients may lose response, have inadequate control of disease, or develop intolerance to certain biologic agents. It may therefore be beneficial for patients whose
Externí odkaz:
https://doaj.org/article/4612677df7ab489a87d73d7e4fd40a9c
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 3, Pp 351-364 (2020)
Abstract Psoriasis (PsO) is a common, systemic, chronic, inflammatory disease characterized by key clinical symptoms, including itching, pain, and scaling. PsO is associated with a high prevalence of comorbidities, including other autoimmune diseases
Externí odkaz:
https://doaj.org/article/3a073057ee944026ab5511fce26d20b5
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 1, Pp 203-211 (2020)
Abstract Introduction Cutaneous body image (CBI) is a construct encompassing how individuals perceive their hair, skin, and nails. Negative CBI has been related to negative psychological outcomes and body image concerns. The first aim of our study wa
Externí odkaz:
https://doaj.org/article/c94daeaf3ba34ce8b1f0984c993437bb
Publikováno v:
JAAD Case Reports, Vol 6, Iss 9, Pp 868-870 (2020)
Externí odkaz:
https://doaj.org/article/e08c4e08e0594dcd801519bacce40fe4
Autor:
Elsie Grace, Orin Goldblum, Lisa Renda, Noah Agada, Kyoungah See, Craig Leonardi, Alan Menter
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 1, Pp 99-106 (2019)
Abstract Introduction Biologics used to treat moderate-to-severe plaque psoriasis may cause injection site reactions (ISRs) characterized by erythema, edema, itch, and sometimes pain. The Federal Adverse Event Reporting System (FAERS) is a repository
Externí odkaz:
https://doaj.org/article/0cc261313ed54acebcb23ebff0d1c0df
Publikováno v:
European Medical Journal Dermatology, Vol 7, Iss 1, Pp 112-123 (2019)
Psoriasis is a chronic, immune-mediated skin condition with systemic involvement, frequently requiring long-term treatment. At present, there are 11 biologic agents available for the treatment of moderate-to-severe psoriasis, which target specific in
Externí odkaz:
https://doaj.org/article/18d6f80fb03746fdb5a42002c8907f94